Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) EBT: 2014-2025

Historic EBT for ImmunityBio (IBRX) over the last 12 years, with Sep 2025 value amounting to -$67.3 million.

  • ImmunityBio's EBT rose 21.51% to -$67.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$348.7 million, marking a year-over-year increase of 40.69%. This contributed to the annual value of -$413.6 million for FY2024, which is 29.16% up from last year.
  • As of Q3 2025, ImmunityBio's EBT stood at -$67.3 million, which was up 27.08% from -$92.3 million recorded in Q2 2025.
  • ImmunityBio's 5-year EBT high stood at -$59.2 million for Q4 2024, and its period low was -$233.5 million during Q4 2023.
  • For the 3-year period, ImmunityBio's EBT averaged around -$117.0 million, with its median value being -$116.6 million (2023).
  • Per our database at Business Quant, ImmunityBio's EBT crashed by 115.58% in 2023 and then soared by 74.65% in 2024.
  • Quarterly analysis of 5 years shows ImmunityBio's EBT stood at -$91.6 million in 2021, then declined by 18.28% to -$108.3 million in 2022, then slumped by 115.58% to -$233.5 million in 2023, then soared by 74.65% to -$59.2 million in 2024, then rose by 21.51% to -$67.3 million in 2025.
  • Its last three reported values are -$67.3 million in Q3 2025, -$92.3 million for Q2 2025, and -$129.9 million during Q1 2025.